Session Time: 8:30am-9:15am
Presentation Time: 8:30am-8:45am
Location: Veterans Auditorium
*Purpose: Erythropoietin (EPO) ligation of the EPO receptor (EPO-R) homodimer and EPO-R/CD131 heterodimer has protolerogenic effects on alloreactive T cell responses. While prior work, largely performed in vitro, showed that EPO-R signaling on T cells suppresses IL-2-induced proliferation and EPO-R signaling on monocytes promotes TGF-β secretion that in turn drives regulatory T cell (Treg) generation, whether/how these effects impact allograft survival in vivo have not been addressed.
*Methods: To test this, we generated EPO-Rfl/fl mice and transplanted groups of EPO-Rfl/fl, EPO-Rfl/fl CD4-cre+ (absent EPO-R on T cells), and EPO-Rfl/fl LysM-cre (absent EPO-R on myeloid cells) B6 recipients with BALB/c hearts. Transplant recipients received a single dose of CTLA4-Ig ± recombinant EPO (rEPO) daily x 3 days.
*Results: Untreated animals of all genotypes rejected their allografts within 8 days (p=ns) and CTLA-Ig alone equivalently prolonged survival of all genotypes to a median survival time (MST) of 20 days (p=ns among groups). Addition of rEPO prolonged graft survival in EPO-Rfl/fl recipients to 35 days (p<0.05 vs. CTLA4-Ig alone). rEPO similarly prolonged graft survival in CTLA4-Ig-treated EPO-Rfl/fl CD4-cre+ recipients (MST 32), indicating that EPO-R signaling on T cells is not required for the effect. In contrast, rEPO administration did not prolong BALB/c heart graft survival in CTLA4-Ig-treated EPO-Rfl/fl LysM-cre+ recipients (MST 16 days, p=ns vs. CTLA4-Ig alone), indicating that EPO-R signaling on myeloid cells is required. We next transplanted additional groups of EPO-Rfl/fl and EPO-Rfl/fl LysM-cre B6 mice (all given CTLA4-Ig+rEPO) and sacrificed them on day 14 post-transplant (all grafts beating) to perform ex vivo mechanistic analyses. These studies revealed a 2-fold increase in donor-reactive IFNγ-producing splenic CD8+ T cells and ~3-fold increase in the ratio of IFNγ-producing T effector cells to Tregs in the EPO-Rfl/fl LysM-cre+ recipients vs the EPO-Rfl/fl controls (p<0.001 for each). When we analyzed intragraft cytokine expression, we observed a 2-fold reduction in the ratio of IL-10 to IL-12 in the EPO-Rfl/fl LysM-cre+ mice vs the EPO-Rfl/fl controls (p<0.05).
*Conclusions: Our data show that rEPO interacts with CTLA4-Ig to prolong allograft survival and that the effects are mediated through EPO-induced alterations in myeloid cells, which in turn enhance Treg function. The findings suggest that post-transplant rEPO therapy could be effective in reducing rejection and improving allograft function in humans.
To cite this abstract in AMA style:Horwitz J, Cravedi P, Heeger P. Exogenous Erythropoietin Administration Promotes Murine Cardiac Allograft Survival via a Myeloid Cell-Dependent Mechanism [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/exogenous-erythropoietin-administration-promotes-murine-cardiac-allograft-survival-via-a-myeloid-cell-dependent-mechanism/. Accessed October 21, 2020.
« Back to 2019 American Transplant Congress